AI Engines For more Details: Perplexity Kagi Labs You
Anti-anginal Effects: Fendiline hydrochloride works by dilating the blood vessels, particularly the coronary arteries that supply blood to the heart muscle. By increasing blood flow to the heart, it helps relieve chest pain associated with angina and may improve exercise tolerance.
Vasodilation: Fendiline hydrochloride acts as a calcium channel blocker, specifically blocking the influx of calcium ions into smooth muscle cells lining blood vessels. This action relaxes and widens the blood vessels, reducing peripheral resistance and lowering blood pressure.
Coronary Blood Flow: By dilating the coronary arteries, fendiline hydrochloride improves blood flow to the heart muscle, which is essential for delivering oxygen and nutrients. This increased coronary blood flow helps alleviate ischemia (lack of oxygen) and reduces the frequency and severity of angina attacks.
Antiarrhythmic Effects: Fendiline hydrochloride may also possess antiarrhythmic properties, meaning it helps stabilize the heart's rhythm. It may be used in certain cases to manage cardiac arrhythmias, although it is primarily indicated for angina treatment.
Side Effects: Common side effects of fendiline hydrochloride may include dizziness, headache, flushing, palpitations, nausea, and gastrointestinal discomfort. These side effects are usually mild and transient but should be reported to a healthcare provider if persistent or bothersome.
Contraindications: Fendiline hydrochloride is contraindicated in individuals with known hypersensitivity to the medication, severe hypotension (low blood pressure), and certain cardiac conditions such as heart failure and cardiogenic shock. It should not be used concomitantly with certain medications, such as other calcium channel blockers and beta-blockers, without medical supervision.
Drug Interactions: Fendiline hydrochloride may interact with other medications, including antiarrhythmics, beta-blockers, and medications that affect cardiac conduction. It is important to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
Dosage and Administration: Fendiline hydrochloride is typically administered orally in the form of tablets or capsules. The dosage and frequency of administration depend on the individual's condition, severity of symptoms, and response to treatment. It is important to follow the healthcare provider's instructions and not exceed the recommended dose.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.8 | -0.33 |
| ADHD | 3.1 | 1.7 | 0.82 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2 | 0.7 |
| Allergies | 7.2 | 2.7 | 1.67 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.5 | 1.5 | |
| Alzheimer's disease | 5.8 | 6.1 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4 | 1 | 3 |
| Ankylosing spondylitis | 4.3 | 1.2 | 2.58 |
| Anorexia Nervosa | 1.3 | 2.9 | -1.23 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 4.9 | 1.4 | 2.5 |
| Atherosclerosis | 2 | 2.4 | -0.2 |
| Atrial fibrillation | 3.5 | 3.1 | 0.13 |
| Autism | 9.8 | 8.8 | 0.11 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2 | 2 | |
| Bipolar Disorder | 1.8 | 0.8 | 1.25 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1.1 | 1.1 | |
| Cancer (General) | 0.3 | 2 | -5.67 |
| Carcinoma | 3.5 | 2.3 | 0.52 |
| Celiac Disease | 3.2 | 2.9 | 0.1 |
| Cerebral Palsy | 1.1 | 1 | 0.1 |
| Chronic Fatigue Syndrome | 3.4 | 6.4 | -0.88 |
| Chronic Kidney Disease | 3.9 | 2.8 | 0.39 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 1.4 | 0.64 |
| Chronic Urticaria (Hives) | 1.6 | 1.2 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1 | 0.8 |
| Cognitive Function | 3.7 | 2.5 | 0.48 |
| Colorectal Cancer | 8.5 | 2.7 | 2.15 |
| Constipation | 2.6 | 1.6 | 0.63 |
| Coronary artery disease | 2.6 | 2.7 | -0.04 |
| COVID-19 | 7.9 | 10.3 | -0.3 |
| Crohn's Disease | 7.9 | 5.2 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.1 | 1.3 | -0.18 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2.7 | 1.1 | 1.45 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 9.7 | 8.5 | 0.14 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.5 | -0.47 |
| Endometriosis | 3.4 | 1.9 | 0.79 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.6 | 1.7 | 1.12 |
| erectile dysfunction | 1.9 | 0.3 | 5.33 |
| Fibromyalgia | 3 | 3.6 | -0.2 |
| Functional constipation / chronic idiopathic constipation | 5.6 | 3.9 | 0.44 |
| gallstone disease (gsd) | 3.6 | 0.8 | 3.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1.2 | 0 |
| Generalized anxiety disorder | 2.7 | 2.2 | 0.23 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 1.1 | -0.22 |
| Graves' disease | 1.3 | 2.7 | -1.08 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 2.9 | 1.6 | 0.81 |
| Heart Failure | 4.6 | 2.5 | 0.84 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
| hypercholesterolemia (High Cholesterol) | 1 | 1 | |
| hyperglycemia | 1.7 | 1.1 | 0.55 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.3 | 4.5 | -0.05 |
| Hypothyroidism | 0.9 | 0.7 | 0.29 |
| Hypoxia | 3.5 | 0.9 | 2.89 |
| IgA nephropathy (IgAN) | 1 | 4.1 | -3.1 |
| Inflammatory Bowel Disease | 7.8 | 8.2 | -0.05 |
| Insomnia | 2.8 | 1.8 | 0.56 |
| Intelligence | 1.9 | 0.6 | 2.17 |
| Intracranial aneurysms | 0.9 | 0.9 | 0 |
| Irritable Bowel Syndrome | 6.7 | 4.2 | 0.6 |
| ischemic stroke | 2.2 | 1.7 | 0.29 |
| Liver Cirrhosis | 6.2 | 3.3 | 0.88 |
| Long COVID | 6.3 | 6.8 | -0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.7 | 0.29 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 1 | 2.4 | -1.4 |
| ME/CFS without IBS | 1.1 | 2.2 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 0.5 | 1.6 |
| Metabolic Syndrome | 7.2 | 6.1 | 0.18 |
| Mood Disorders | 8.6 | 7.3 | 0.18 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 6.1 | 7.4 | -0.21 |
| Multiple system atrophy (MSA) | 0.6 | 0.4 | 0.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.1 | -2.1 | |
| Neuropathy (all types) | 0.4 | 2.6 | -5.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.9 | 3.7 | 0.32 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 9.2 | 6.9 | 0.33 |
| obsessive-compulsive disorder | 5.5 | 4.1 | 0.34 |
| Osteoarthritis | 3 | 0.9 | 2.33 |
| Osteoporosis | 2.2 | 1.6 | 0.38 |
| pancreatic cancer | 1.2 | 0.6 | 1 |
| Parkinson's Disease | 8.1 | 7.9 | 0.03 |
| Polycystic ovary syndrome | 6.6 | 2.3 | 1.87 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 1.8 | 2.8 | -0.56 |
| Psoriasis | 3.2 | 3.2 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 4.1 | 0.71 |
| Rosacea | 0.8 | 1 | -0.25 |
| Schizophrenia | 5.2 | 2.5 | 1.08 |
| scoliosis | 0.8 | 0.9 | -0.13 |
| Sjögren syndrome | 2.3 | 2.6 | -0.13 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.3 | 4.33 |
| Stress / posttraumatic stress disorder | 2.8 | 2.1 | 0.33 |
| Systemic Lupus Erythematosus | 4 | 2.1 | 0.9 |
| Tic Disorder | 1.2 | 2.9 | -1.42 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.4 | 3.6 | 0.22 |
| Type 2 Diabetes | 8.2 | 6.9 | 0.19 |
| Ulcerative colitis | 5.7 | 7.2 | -0.26 |
| Unhealthy Ageing | 5.1 | 2.4 | 1.13 |
| Vitiligo | 2.2 | 1.5 | 0.47 |
